{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-23-000146","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.102348+00:00","generated_at":"2026-06-08T23:55:31.120644+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Castle Biosciences Q3 revenue $61.5M (+66% YoY), raises FY2023 guidance to at least $200M","bullets":["Q3 revenue $61.5M, up 66% YoY; adjusted revenue $60.6M, up 63%.","Total test reports 18,409 (+52% YoY); DecisionDx-Melanoma 8,559 (+16%), TissueCypher 2,829 (+310%).","Net loss narrowed to $(6.9)M from $(20.2)M; adjusted EBITDA $6.6M vs $(9.6)M.","Raised FY2023 revenue guidance to at least $200M from at least $180M.","Operating cash flow positive $5.0M; cash $229.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-23-000146","json":"https://secwatch.observer/filing/0001447362-23-000146.json","markdown":"https://secwatch.observer/filing/0001447362-23-000146.md","text":"https://secwatch.observer/filing/0001447362-23-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/0001447362-23-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/cstl-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:55:31.120644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ed26fed339406f4ecc2ff56bc6bafd535e7e167","claim":"CASTLE BIOSCIENCES INC reported the third quarter ended September 30, 2023 results: revenue $61.5 million, net income $(6.9) million. Guidance raised.","evidence_excerpt":"Revenues were $61.5 million, a 66% increase compared to $37.0 million during the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/0001447362-23-000146-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$61.5 million"},{"label":"Net income","value":"$(6.9) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c7e7235c94c7539570d6cd94eeda9378e3c40fb1","claim":"CASTLE BIOSCIENCES INC reported the nine months ended September 30, 2023 results: revenue $153.7 million, net income $(54.9) million.","evidence_excerpt":"Revenues were $153.7 million, a 56% increase compared to $98.7 million during the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/0001447362-23-000146-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2023"},{"label":"Revenue","value":"$153.7 million"},{"label":"Net income","value":"$(54.9) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}